Related Experiment Videos
Failure of immunotherapy for metastatic renal cell carcinoma
Abstract:
Prompted by reports of tumor regression among patients with metastatic renal cell carcinoma treated by injection of an aggregated autologous or allogeneic tumor antigen with a nonspecific adjuvant, we studied the efficacy of this therapy in 23 patients. Following nephrectomy or excision of a metastatic lesion 16 patients were treated with an aggregated autologous tumor antigen combined with Candida albicans antigen. There were only 2 minimal responses. Seven patients judged unsuitable for an operation were treated with an aggregated allogeneic antigen. There were no objective responses. We conclude that these treatment regimens have minimal activity against metastatic renal cell carcinoma.
Insights
This study investigated tumor antigen injections for metastatic renal cell carcinoma. The treatment showed minimal efficacy, with only two minimal responses observed in 23 patients with advanced kidney cancer.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma Research
Background:
- Reports suggested tumor regression in metastatic renal cell carcinoma (mRCC) patients treated with aggregated tumor antigen and adjuvant.
- This prompted an investigation into the efficacy of such immunotherapy approaches.
Purpose of the Study:
- To evaluate the clinical efficacy of aggregated autologous or allogeneic tumor antigen combined with a nonspecific adjuvant in patients with metastatic renal cell carcinoma.
- To determine the response rates and overall activity of this immunotherapeutic strategy.
Main Methods:
- A total of 23 patients with metastatic renal cell carcinoma were included in the study.
- Sixteen patients received aggregated autologous tumor antigen with Candida albicans antigen post-nephrectomy or metastasis excision.
- Seven patients unsuitable for surgery received aggregated allogeneic antigen.
Main Results:
- Only two minimal responses were observed among the 16 patients treated with autologous antigen.
- No objective responses were recorded in the seven patients who received allogeneic antigen.
- The overall activity of the studied treatment regimens against metastatic renal cell carcinoma was found to be minimal.
Conclusions:
- The investigated treatment regimens involving aggregated tumor antigens and nonspecific adjuvants demonstrate limited clinical activity in patients with metastatic renal cell carcinoma.
- Further research may be needed to explore alternative or modified immunotherapeutic strategies for this patient population.